Optometrists in Woodbury, NJ Accepting Medicare
6 Optometrists found. Showing 1 - 6
 James E Zimmerman, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1750 Deptford Center Rd, Deptford Mall # 1172, Woodbury, NJ 08096 Phone: 856-848-6400 |
 Dale Stein And Associates, O.d.,p.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1750 Clements Bridge Rd, 2e5b Deptford Mall, Woodbury, NJ 08096 Phone: 856-384-0388 Fax: 856-384-6405 |
 Louise Colletti, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 661 N Broad St, Woodbury, NJ 08096 Phone: 856-845-7968 Fax: 856-845-8544 |
Ami Dinesh Patel, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1750 Deptford Center Rd, Woodbury, NJ 08096 Phone: 856-848-3162 Fax: 856-848-5657 |
Patient Care Medical Group Pc Optometrist Medicare: Medicare Enrolled Practice Location: 467 Cooper St, Woodbury, NJ 08096 Phone: 609-385-2622 Fax: 856-520-8239 |
Dr. Lawrence Anthony Duda, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1750 Deptford Center Rd, J C Penney Optical, Woodbury, NJ 08096 Phone: 856-384-6125 Fax: 856-845-0884 |
News Archive
Study finds reduction in pain favoring Mynx Vascular Closure Device to Angio-Seal Evolution Device
AccessClosure, Inc., the U.S. market segment leader in extravascular closure devices, announced today results from the first published study (Journal of NeuroInterventional Surgery) comparing the pain associated with deployment of different vascular closure devices (VCD) as the primary endpoint.
Xpert diagnosis of TB and its drug resistant strains
The use of a novel, diagnostic test called Xpert is both sensitive and specific in detecting tuberculosis and rifampicin resistance, report US researchers.
Initial insight into sedentary behavior counseling practices in primary care settings
Although primary care physicians take care of many aspects of health and disease, little is known about how they can change sedentary behavior through counseling, according to researchers at The University of Texas Health Science Center at Houston (UTHealth).
Merck acquires development, commercialization rights of ridaforolimus
Merck today announced that it has restructured its co-development and co-commercialization agreement with ARIAD Pharmaceuticals, Inc. for ridaforolimus, an investigational orally available mTOR inhibitor currently being evaluated for the treatment of multiple cancer types, to an exclusive license agreement.
› Verified 6 days ago
Podiatrists
Physical Therapists
Chiropractors
Optometrists
Audiologists
Speech-Language Pathologists
Occupational Therapists